What is seqWell?
Headquartered in Beverly, Massachusetts, seqWell is a global provider of advanced NGS library construction technologies. The company is best known for its plexWell platform, which significantly enhances the efficiency and scalability of sample preparation for NGS instrumentation. By engineering streamlined application workflows, seqWell addresses critical bottlenecks in genomic analysis, providing researchers with the tools necessary to improve data quality and utility. Its market position is defined by a focus on high-performance solutions that simplify complex laboratory processes, making it an essential partner for organizations operating across the biopharma and clinical diagnostics landscapes.
How much funding has seqWell raised?
seqWell has raised a total of $17.4M across 4 funding rounds:
Private Equity
$1.3M
Series B
$9M
Debt
$150K
Series C
$7M
Private Equity (2016): $1.3M, investors not publicly disclosed
Series B (2020): $9M led by Research and BroadOak Fund
Debt (2020): $150K supported by PPP
Series C (2022): $7M featuring Research, Codexis, and BroadOak Capital Partners
Key Investors in seqWell
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies.
Codexis
Codexis, Inc. is a leading enzyme engineering company that leverages its proprietary CodeEvolver platform to develop high-performance proteins for therapeutics and diagnostics.
Research Corporation Technologies
Research Corporation Technologies develops specialized expression technologies, including genetically modified strains designed for endotoxin-free protein and DNA production.
What's next for seqWell?
With the successful closure of its latest financing round, seqWell is well-positioned to scale its commercial operations and further penetrate the global genomics market. The strategic deployment of this capital will likely focus on the continued optimization of the plexWell platform and the expansion of its application portfolio to meet the evolving needs of high-throughput sequencing facilities. As the demand for rapid, high-quality genomic data continues to rise, seqWell's focus on enzymatic innovation and workflow automation will be critical in maintaining its competitive edge. The company is expected to leverage these resources to strengthen its strategic partnerships and accelerate the adoption of its technologies in both research and clinical settings, ultimately driving long-term value for its stakeholders and the broader scientific community.
See full seqWell company page
